Modern Slavery and Human Trafficking Statement

1. Introduction  

This statement sets out Feature Medical’s actions to understand all potential modern slavery risks related to its business, and to put in place steps to ensure there is no slavery or human trafficking within its own business or its supply chains.

This statement relates to actions and activities during the financial year 1st April 2023 to 31st March 2024.

As a Medical Services provider, we recognise that we have a responsibility to take a robust approach to slavery and human trafficking.

Feature Medical is committed to preventing slavery and human trafficking in its activities, and to ensuring that its supply chains are free from slavery and human trafficking.

2. Company structure and supply chains  

This statement covers the activities of Feature Medical Limited, who provide:

  • Medical Services (primarily to the Film and TV Production Industry)

  • Medical Concierge Services (primarily to Film, TV Production and Sports Industries.)

    Responsibility for our anti-slavery initiatives is as follows:

    Policies: icies and procedures are developed by the key specialists within the business with the support of our Governance Structure and with guidance and ongoing monitoring from the Management Team.

    Risk assessments: The Board has assessed that the risk of slavery and human trafficking occurring in our business and supply chains is very low, given the nature of our business and our governance model. However, we aim to regularly review the effectiveness of the relevant policies and procedures as part of our Quality Management cycle.

    3. Relevant policies 

    We operate the following policies that describe our approach to the identification of modern slavery risks and steps to be taken to prevent slavery and human trafficking in our operations:

    Whistleblowing policy We encourage all our workers, customers, and other business partners to report any concerns related to the direct activities, or the supply chains of, our business. This includes any circumstances that may give rise to an enhanced risk of slavery or human trafficking. Our whistleblowing procedure is designed to make it easy for workers to make disclosures, without fear of retaliation. Employees, customers, or others who have concerns can report this in confidence via our Blink Communication platform or via our website.

    Employee code of conduct Our code makes clear to employees the actions and behaviour expected of them when representing the business. We strive to maintain the highest standards of employee conduct and ethical behaviour and particularly in managing our supply chain.

    Procurement/Supplier relationships We are committed to ensuring that our suppliers adhere to high standards of ethics. Suppliers are required to demonstrate that they provide safe working conditions where necessary, treat workers with dignity and respect, and act ethically and within the law in their use of labour. Failure to align to our ethical values will potentially lead to the termination of the business relationship.

    Agency workers policy e use only specified, reputable employment agencies to source labour and always verify the practices of any new agency before accepting workers from that agency. We do not currently use agency labour.

    4. Due diligence  

    We undertake due diligence when considering taking on new suppliers, and regularly review existing suppliers. Our due diligence and reviews include:

  • conducting supplier assessments as part of the QMS system, which have a degree of focus on slavery and human trafficking where general risks are identified.

  • conducting supplier assessments as part of the QMS system, which have a degree of focus on slavery and human trafficking where general risks are identified.

  • invoking sanctions against suppliers that fail to improve their performance in line with any action plan agreed, including the potential termination of the business relationship.

    5. Board/Member approval 

    This statement was approved on 5th April 2024 by our Board of Directors, who review and update it annually.

  • To top